期刊文献+

顺铂化疗对下丘脑、血浆ghrelin和orexin表达的影响 被引量:1

Effects of Orexin on the Cisplatin-induced Pica in Rats
原文传递
导出
摘要 目的:观察顺铂化疗对下丘脑、血浆ghrelin、orexin表达和摄食量的影响。方法:Real-time PCR、ELISA法观察顺铂对大鼠下丘脑、血浆ghrelin、orexin表达及摄食量的影响;19名接受顺铂经导管动脉灌注化疗(TAI)的肝细胞患者(HCC),ELISA法检测化疗前和化疗后血浆ghrelin、orexin的变化,用直观类比标度(VAS)(0-10)评估食欲和摄食量。结果:每日腹腔注射顺铂6 mg/kg,1-5 d大鼠摄食量均显著减少(P〈0.05),且1-4 d血浆酰化ghrelin显著降低(P〈0.05),5d时浓度仍低于对照组,但无统计学意义。血浆非酰化ghrelin和总的血浆ghrelin没有明显变化(P〉0.05),而1-5天血浆orexin水平均明显降低(P〈0.05);顺铂注射1 d后,大鼠下丘脑ghreilin和orexin的mRNA表达量均显著减少(P〈0.05),ghrelin mRNA变化持续3 d,orexin mRNA在化疗后5 d仍低于对照组(P〈0.05);肝细胞癌患者化疗后1至8 d的摄食量明显降低,1 d和2 d时的血浆酰化ghrelin显著低于化疗前水平(P〈0.05)。3 d时逐渐恢复,化疗后3 d、4 d和7 d时血浆酰化ghrelin浓度与化疗前无统计学差异(P〉0.05)。血浆非酰化ghrelin和总的血浆ghrelin没有明显变化(P〉0.05);化疗后1~4 d时血浆orexin浓度均显著降低(P〈0.05),化疗后7 d时orexin基本恢复到化疗前水平(P〉0.05)。结论:顺铂可降低大鼠下丘脑和血浆ghrelin、orexin的mRNA表达,HCC的TAI会降低血浆酰化ghrelin、orexin、和摄食量。 Objective: To observe the effect of cisplatin on plasma ghrelin, orexin expression in the hypothalamus and the influence of food intake. Methods: Real- time PCR and ELISA method to observe the cisplatin on rat hypothalamus, plasma ghrelin, orexin expression and the influence of food intake; 19 cisplatin transcatheter arterial infusion chemotherapy(TAI) of liver cells(HCC) patients,ELISA method to detect plasma ghrelin chemotherapy before and after chemotherapy, the change of orexin, using visual analog scale(VAS)(0 to 10) evaluation appetite and food intake. Results: Daily intraperitoneal injection of cisplatin 6 mg/kg, 1-5 d food intake in rats were significantly reduced(P〈0.05), and 1-4 d plasma acylation ghrelin significantly reduced(P〈0.05), 5 d concentration is still lower than the control group, but no statistical significance. Plasma ghrelin plasma of acylation ghrelin and general no significant change(P〉0.05), and 1-5 days plasma orexin levels were significantly lower(P〈0.05); Cisplatin injection after 1 d, rat hypothalamus ghreilin and orexin mRNA expression were significantly reduced(P〈0.05), ghrelin mRNA for 3 d change, orexin mRNA in 5 d after chemotherapy is still lower than the control group(P〈0.05); Hepatocellular carcinoma(HCC) patients after chemotherapy significantly lower intake for 1 to 8 d, 1 d and 2 d plasma acylation ghrelin is significantly below the level before chemotherapy(P〈0.05). Returning when 3 d, 3 d, 4 d and 7 d after chemotherapy when the plasma concentration of acylation ghrelin and chemotherapy before no statistical difference(P〉0.05).Plasma of acylation ghrelin and total plasma ghrelin there was no significant change(P〉0.05); After chemotherapy when 1~4 d plasma orexin concentrations were significantly lower(P〈0.05), 7 d after chemotherapy when orexin basic to return to the front of the chemotherapy(P〉0.05). Conclusion: Cisplatin can reduce rat hypothalamus and plasma ghrelin and orexin mRNA expression, HCC TAI lowers plasma acylation ghrelin, orexin, and food intake.
出处 《现代生物医学进展》 CAS 2016年第31期6023-6027,6041,共6页 Progress in Modern Biomedicine
基金 国家自然科学基金项目 (81270460 81470815 81500414 81300281) 山东省优秀中青年科学家科研奖励基金资助项目(BS2014YY009) 青岛市公共领域科技支撑计划(14-2-3-3-nsh)
关键词 顺铂 OREXIN GHRELIN 大鼠 Cisplatin Orexin Ghrelin Rat
  • 相关文献

参考文献2

二级参考文献20

  • 1Van Cutsem E,Peeters M,Siena S,et al.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology . 2007
  • 2Elena De Mattia,Giuseppe Toffoli,Jerry Polesel,Mario D’Andrea,Giuseppe Corona,Vittorina Zagonel,Angela Buonadonna,Eva Dreussi,Erika Cecchin.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment[J].Pharmacogenetics and Genomics.2013(10)
  • 3KimieSai,YoshiroSaito,NaokoTatewaki,MasakiyoHosokawa,NahokoKaniwa,TomokoNishimaki‐Mogami,MikihikoNaito,Jun‐ichiSawada,KuniakiShirao,TetsuyaHamaguchi,NoboruYamamoto,HideoKunitoh,TomohideTamura,YasuhideYamada,YuichiroOhe,TeruhikoYoshida,HironobuMinami,AtsushiOhtsu,YasuhiroMatsumura,NagahiroSaijo,HaruhiroOkuda.Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients[J]. British Journal of Clinical Pharmacology . 2010 (2)
  • 4Leonard B. Saltz,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,Tsai-Shen Yang,Fern,o Rivera,Felix Couture,Florin Sirzén,Jim Cassi.Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Japanese Journal of Clinical Oncology . 2008
  • 5Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian Lerchenmüller,Christoph Kahl,Gernot Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,J?rg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert H?ffkes,Markus Moehler,Reinhard U Lindig,Dominik P Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncology . 2014 (10)
  • 6Jie Li,Yu Wan,Shufang Na,Xiaochan Liu,Guicheng Dong,Zheqiong Yang,Jing Yang,Jiang Yue.Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα[J]. Biochemical Pharmacology . 2014
  • 7Ken-ichi Fujita,Tomoko Sugiura,Hidenori Okumura,Saki Umeda,Noritaka Nakamichi,Yusuke Watanabe,Hiromichi Suzuki,Yu Sunakawa,Ken Shimada,Kaori Kawara,Yasutsuna Sasaki,Yukio Kato.Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans[J]. Pharmaceutical Research . 2014 (1)
  • 8Y Claire Wang,Klim McPherson,Tim Marsh,Steven L Gortmaker,Martin Brown.Health and economic burden of the projected obesity trends in the USA and the UK[J]. The Lancet . 2011 (9793)
  • 9Michael H. Court.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system[J]. Drug Metabolism Reviews . 2010 (1)
  • 10Hiroshi Takane,Katsuyuki Kawamoto,Tomohiro Sasaki,Kuniaki Moriki,Kazuyo Moriki,Hiroya Kitano,Shun Higuchi,Kenji Otsubo,Ichiro Ieiri.Life-threatening toxicities in a patient with UGT1A1 * 6 /* 28 and SLCO1B1 * 15 /* 15 genotypes after irinotecan-based chemotherapy[J]. Cancer Chemotherapy and Pharmacology . 2009 (6)

共引文献30

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部